← Back to Clinical Trials
Recruiting NCT07112989

NCT07112989 Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07112989
Status Recruiting
Phase
Sponsor Istituto Ortopedico Rizzoli
Condition Bone and Soft Tissue Tumors
Study Type OBSERVATIONAL
Enrollment 125 participants
Start Date 2024-09-23
Primary Completion 2031-09-23

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 85 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 125 participants in total. It began in 2024-09-23 with a primary completion date of 2031-09-23.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to learn how tumor tissue and blood samples from patients with sarcomas or metastases can be used to create laboratory models that help researchers study cancer behavior and test new treatments. Participants diagnosed with sarcoma or with bone or lung metastases from solid tumors will donate leftover tumor tissue and blood collected during their regular medical care. These samples will be used in the lab to build 3D models of the tumor, test drugs, and identify genetic and molecular markers. No treatments or procedures will be given as part of the study.

Eligibility Criteria

Inclusion Criteria: * Patients (male or female) diagnosed with sarcoma or with bone or lung metastases from solid tumors * Age between 0 and 85 years * Availability of sufficient and adequate biological material (tumor tissue and/or blood) * Signed informed consent for biobanking (BIOTUM) * Signed informed consent for use of tissue and blood samples in this study Exclusion Criteria: * Diagnosis other than sarcoma or metastases from solid tumors * Missing signed informed consent(s)

Contact & Investigator

Central Contact

Toni Ibrahim, MD Oncologist

✉ toni.ibrahim@ior.it

📞 +39 0516366199

Frequently Asked Questions

Who can join the NCT07112989 clinical trial?

This trial is open to participants of all sexes, up to 85 Years, studying Bone and Soft Tissue Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07112989 currently recruiting?

Yes, NCT07112989 is actively recruiting participants. Contact the research team at toni.ibrahim@ior.it for enrollment information.

Where is the NCT07112989 trial being conducted?

This trial is being conducted at Bologna, Italy.

Who is sponsoring the NCT07112989 clinical trial?

NCT07112989 is sponsored by Istituto Ortopedico Rizzoli. The trial plans to enroll 125 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology